Samsung And Biogen Join For Biosimilars | Chemical & Engineering News
Volume 89 Issue 50 | p. 17 | Concentrates
Issue Date: December 12, 2011

Samsung And Biogen Join For Biosimilars

Department: Business
Keywords: manufacturing, biosimilars, pharmaceuticals, Korea

Biogen Idec has agreed to set up a joint venture in South Korea with Samsung to develop, make, and sell biosimilars, or generic versions of biologic drugs. Samsung, which created a biopharmaceutical manufacturing business in April, will invest $225 million in the venture. Biogen will contribute $45 million, along with protein engineering and biologics manufacturing expertise. The joint venture will not pursue biosimilar versions of Biogen’s products.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment